AbelZeta Receives EMA PRIME Designation for C-CAR168 in Lupus Nephritis and Systemic Lupus Erythematosus

RegulatoryC-CAR168Positive

AI Analysis

Summary

AbelZeta Pharma announced that its cell-based therapeutic C-CAR168 has received EMA PRIME designation for the treatment of Lupus Nephritis and Systemic Lupus Erythematosus, accelerating the regulatory pathway for this clinical-stage candidate.

Outcome Details

EMA PRIME Designation granted

Importance:6/10

Sentiment:

0.85

EMA PRIMERegulatory DesignationCell-based TherapyLupus NephritisSystemic Lupus Erythematosus

Related Companies

$GBCYD

Read the original article

Published by PR Newswire Pharma on July 20, 2026 2:19 PM

Read Original